GRANULESNSEGranules India Limited· PharmaceuticalsHighNeutral
Announced Fri, 1 Aug · 14:12 IST

The Exchange has sought clarification from Granules India Limited with respect to recent news item captioned Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices. The response from the Company is attached.

Regulatory & Legal View source PDF

GRANULES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

NSE sought clarification from Granules India after its share price dropped following a Moneycontrol news item about Trump sending letters to 17 global pharma majors seeking lower drug prices. The company clarified that it has NOT received any communication from the US government or any related authority. Granules India is not among the 17 companies listed (which include AbbVie, Pfizer, Merck, Novartis, etc.). There are no ongoing negotiations, regulatory proceedings, or undisclosed price-sensitive information related to this matter. The company confirmed full compliance with SEBI disclosure regulations and stated the news item does not factually apply to it.

Likely market impact

This clarification should reassure investors that the stock movement was due to broad sector-wide sentiment rather than any company-specific action against Granules India. Short-term sentiment may recover as the company's non-involvement is confirmed, though the pharma sector may remain under pressure from US drug pricing concerns.